 Proactive Investors USA & Canada | Cell Therapeutics shares surge on commercial launch of lymphoma drug in ... Proactive Investors USA & Canada The company said it is also currently accruing patients into a phase 3 trial comparing pixantrone and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. European sites will be participating in this study later this year. |
